Cardinal Health (CAH)
(Delayed Data from NYSE)
$111.93 USD
-0.62 (-0.55%)
Updated Oct 17, 2024 04:00 PM ET
After-Market: $111.94 +0.01 (0.01%) 7:58 PM ET
2-Buy of 5 2
A Value A Growth B Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$111.93 USD
-0.62 (-0.55%)
Updated Oct 17, 2024 04:00 PM ET
After-Market: $111.94 +0.01 (0.01%) 7:58 PM ET
2-Buy of 5 2
A Value A Growth B Momentum A VGM
Zacks News
Quest Diagnostics (DGX) Hurt by Lower Testing Sales, Competition
by Zacks Equity Research
Quest Diagnostics (DGX) faces intense competition, primarily from LabCorp as well as other commercial laboratories and hospitals.
Veeva Systems (VEEV) Q4 Earnings Surpass Estimates, Margins Up
by Zacks Equity Research
Veeva Systems' (VEEV) fiscal Q4 results reflect impressive performances by both segments.
Here's Why You Should Retain Omnicell (OMCL) Stock Now
by Zacks Equity Research
Investors are optimistic about Omnicell (OMCL) moving closer to achieving its vision of Autonomous Pharmacy.
Bruker (BRKR) Inks Definitive Agreement to Acquire ELITechGroup
by Zacks Equity Research
Bruker (BRKR) announces a share purchase agreement to acquire the molecular diagnostics innovator ELITechGroup.
Veradigm (MDRX) to Acquire AI Service Provider ScienceIO
by Zacks Equity Research
Veradigm (MDRX) is set to acquire ScienceIO to benefit its Provider, Payer and Life Sciences businesses, offering highly differentiated and advanced products to its customers.
Cooper Companies (COO) Q1 Earnings Top, '24 Outlook Raised
by Zacks Equity Research
Cooper Companies' (COO) first-quarter fiscal 2024 revenues reflect a solid segmental performance with improved adjusted earnings amid rising expenses.
New Strong Buy Stocks for March 1st
by Zacks Equity Research
BMA, CAH, RCL, SPXC and RITM have been added to the Zacks Rank #1 (Strong Buy) List on March 1, 2023.
Best Income Stocks to Buy for March 1st
by Zacks Equity Research
BMA, CAH and RITM made it to the Zacks Rank #1 (Strong Buy) income stocks list on March 1, 2023.
Inari Medical (NARI) Q4 Earnings Improve Y/Y, Gross Margin Down
by Zacks Equity Research
Inari Medical's (NARI) fourth-quarter earnings miss, while sales match estimates. Gross margin improves while the company incurs losses at the operating level.
Merit Medical (MMSI) Q4 Earnings Top Estimates, Gross Margin Up
by Zacks Equity Research
Merit Medical (MMSI) benefits from revenue growth in both segments and all product categories within its Cardiovascular unit in the fourth quarter.
Integra's (IART) Q4 Earnings Miss Estimates, Margins Down
by Zacks Equity Research
Integra's (IART) Q4 revenues are impacted by the decline in the Tissue Technologies segment.
Cardinal Health, Inc. (CAH) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Cardinal (CAH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
DENTSPLY SIRONA (XRAY) Q4 Earnings Beat Estimates, Sales Up Y/Y
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) Q4 revenues improve year over year. Challenging macro headwinds linger.
National Vision (EYE) Q4 Earnings Top Estimates, Margins Fall
by Zacks Equity Research
National Vision's (EYE) Q4 adjusted comparable store sales growth is driven by ongoing strength within America's Best and Eyeglass World sales.
Nevro (NVRO) Gets FDA Nod for SI Fixation Without Lateral Screw
by Zacks Equity Research
Nevro's (NVRO) SI joint fusion device, Nevro1, gets FDA clearance for the use of a lateral screw NevroFix.
Chemed (CHE) Q4 Earnings Surpass Estimates, Margins Expand
by Zacks Equity Research
Chemed's (CHE) fourth-quarter 2023 performance reflects an improvement in VITAS' operational metrics.
3 Reasons Why Growth Investors Shouldn't Overlook Cardinal (CAH)
by Zacks Equity Research
Cardinal (CAH) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Philips' (PHG) New Innovation to Boost Neurovascular Diagnosis
by Zacks Equity Research
Philips (PHG) announces its latest Azurion neuro biplane system, which aims to improve the diagnosis of stroke and major neurovascular diseases. The system is designed for superior patient care.
Patterson Companies (PDCO) Misses on Q3 Earnings, Lowers EPS View
by Zacks Equity Research
Patterson Companies' (PDCO) third-quarter fiscal 2024 results reflect an improvement in Dental Consumable sales, offset by lower Dental Equipment sales. Animal health sales appear weak.
Inogen (INGN) Q4 Earnings Miss Estimates, Gross Margin Improves
by Zacks Equity Research
Inogen's (INGN) fourth-quarter earnings and revenues miss their respective consensus estimate. Gross margin expands while the company continues to incur losses at the operating level.
Masimo (MASI) Q4 Earnings Beat Estimates, Margins Decline
by Zacks Equity Research
Despite strength in the Hearables category, Masimo's (MASI) overall fourth-quarter results reflect soft performances.
OPKO Health's (OPK) Q4 Earnings Match Estimates, Revenues Top
by Zacks Equity Research
Despite OPKO Health's (OPK) robust RAYALDEE sales and strength in the Pharmaceuticals segment, its overall fourth-quarter results reflect soft performances.
Insulet (PODD) Q4 Earnings, Revenues Top Mark, Margins Expand
by Zacks Equity Research
In the fourth quarter, Insulet (PODD) achieves the milestone of 425,000 estimated active global customers using Omnipod products.
Myriad Genetics (MYGN) Q4 Earnings Top Estimate, Margins Down
by Zacks Equity Research
Myriad Genetics (MYGN) registers a strong testing volume improvement across all its businesses in the fourth quarter of 2023.
Alcon (ALC) Q4 Earnings Beat Estimates, Margins Expand
by Zacks Equity Research
Alcon (ALC) delivers impressive performance across its franchises in the fourth quarter of 2023.